PDGFR in myeloproliferative neoplasms

1 EU-approved indication in myeloproliferative neoplasms needs a PDGFR result: imatinib (advanced).

Disease

Line of therapy

Approved indications, Myeloproliferative neoplasms
DrugBiomarker requirementRegimenSettingConditions
FIP1L1::PDGFRA fusion1
Imatinib
Glivec
FIP1L1-PDGFRalpha rearrangement
Monotherapy
Any line
advanced
HES or CEL only

6 approvals for MPN need no biomarker and apply whatever the result. All approvals for MPN

See also

Label wording1

The sentence from section 4.1 of the SmPC that each indication above comes from.

  1. Imatinib (Glivec)
    adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRα rearrangement.